Follow-up of Recovery Condition in Survivors of Acute Respiratory Distress Syndrome
Study Details
Study Description
Brief Summary
Hope to realize the recovery condition of ARDS survivors in Taiwan. It would be helpful not only to design the proper rehabilitation program but also to be a useful reference for the poor recovery patients to take hospice care if indicated.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Detailed Description
This study will enroll the participant met the diagnostic criteria of ARDS. The basic data, clinical manifestations, laboratory data and outcomes of participants will be recorded.
And the investigator will also follow up the pulse oximeter, peak expiratory flow rate, six-minute walk test and health-related quality of life measures with SF-36 in 3, 6 and 12 months after the participants were discharged from the ICU. Through this study, the investigator hope to realize the recovery condition of ARDS survivors in Taiwan.
It would be helpful not only to design the proper rehabilitation program but also to be a useful reference for the poor recovery patients to take hospice care if indicated.
Study Design
Outcome Measures
Primary Outcome Measures
- occurrence of postextubation stridor [24 hours]
To determine whether treatment with corticosteroids decreases the incidence of postextubation airway obstruction in an adult intensive care unit.
Secondary Outcome Measures
- The actual tidal volume at expiration [24 hours]
The actual tidal volume at expiration was measured before and after deflation of the endotracheal tube cuff as previously described (9). The difference in the actual tidal volume before and after cuff deflation was defined as the cuff leak volume (CLV).
Eligibility Criteria
Criteria
Inclusion Criteria:
- ARDS patients
Exclusion Criteria:
- NA
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Chimei Medical Center
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CMFHR10362(IRB10308-011)